Clinical implications of statin event trials.

Anne Carol Goldberg

Abstract readMeta-Analysis

In one paragraph

Synthesis in Current atherosclerosis reports, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Anne Carol GoldbergLipid Research Center, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8046, St. Louis, MO 63110, USA. agoldber@im.wustl.edu

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Event trials using statin therapy have shown a beneficial effect on rates of cardiovascular events. The three statins that have been used in long-term trials have shown generally similar effects on rates of myocardial infarction, stroke, revascularizations, and mortality. Safety data appear to be comparable for lovastatin, pravastatin, and simvastatin. Long-term trials of other statins are in progress or pending. The question of how much low-density lipoprotein cholesterol should be lowered may be answered by studies currently in progress.

Indexed as

Coronary DiseaseDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHyperlipidemiasMalePrimary PreventionRandomized Controlled Trials as TopicRisk AssessmentSeverity of Illness IndexSurvival AnalysisTreatment OutcomeHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

PMID12162932

DOI10.1007/s11883-002-0070-y

What OpenQuestion holds

Texttitle and abstract

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.